2015, Number 5
<< Back Next >>
Rev Fac Med UNAM 2015; 58 (5)
The influence of estrogens in lung cancer
Rodríguez-Lara V, Báez-Saldaña R, Peña-Mirabal E, Vázquez-Manríquez ME, González-Sánchez I, Cerbón-Cervantes MA, Esparza-Silva AL, Fortoula TI
Language: Spanish
References: 29
Page: 5-12
PDF size: 1052.66 Kb.
ABSTRACT
Lung cancer is currently a worldwide health issue because of
the mortality and high incidence of this pathology in both
men and women. The most common form of lung cancer
is adenocarcinoma (ADC); It is an interesting disease entity
because among every type of lung cancer it has the lower
association with smoking and a significant percentage of patients with adenocarcinoma are not smokers. Hence other
factors such as exposure to wood-smoke, air pollutants,
family history of cancer, among others, are important in the
development of lung ADC. Nowadays, lung ADC is the main
form of lung cancer in women and reports show that premenopausal
women have the worse prognosis and have
more aggressive tumors compared to men and postmenopausal
women. These data suggests that estrogens have a
particular role in lung cancer physiopathology mainly in ADC.
Although there is sufficient epidemiological evidence that
indicates a relationship between sexual hormones and lung
cancer, the role of estrogens in this pathology is still controversial.
Furthermore there is no general consent regarding
the known mechanisms by which these hormones could
promote carcinogenesis and because the scarce information
about the implication of these hormones in lung carcinogenesis
more studies are needed. In this review we discuss the
role and relevance of estrogens in lung cancer, a pathology
whose hormonal dependency is becoming clearer
REFERENCES
Globocan. Lung Cancer Incidence and Mortality Worldwide in 2012 Summary. Lyon France: IARC; 2012 [cited 2014].
Wang T, Nelson RA, Bogardus A, Grannis FW, Jr. Fiveyear lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 2010;116(6):1518-25.
Yang P, Cerhan JR, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, et al. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol. 2002;156(12): 1114-22.
Turner MC, Krewski D, Pope CA, 3rd, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never- smokers. American journal of respiratory and critical care medicine. 2011;184(12):1374-81.
Hernandez-Garduno E, Brauer M, Perez-Neria J, Vedal S. Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis. 2004; 8(3):377-83.
Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR, Tata LJ. The association between smoking quantity and lung cancer in men and women. Chest. 2013;143(1):123-9.
Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol. 2012;86(10):1491-504.
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87(3):905-31.
Tam A, Morrish D, Wadsworth S, Dorscheid D, Man SF, Sin DD. The role of female hormones on lung function in chronic lung diseases. BMC Womens Health. 2011;11:24.
Gandy S. Estrogen and neurodegeneration. Neurochem Res. 2003;28(7):1003-8.
Massaro D, Massaro GD. Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice. Am J Physiol-Lung C. 2004;287(6):L1154-L9.
Rodriguez-Lara V E-SA, Mendoza-Rodríguez CA, Cerbón- Cervantes MA, Fortoul TI. Role of estrogen receptors in some respiratory diseases In: Chen G, editor. Estrogen Receptors: Mechanisms, Structure and Role in Disease: Nova science publishers; 2012. p. 149-63.
Pata O, Atis S, Oz AU, Yazici G, Tok E, Pata C, et al. The effects of hormone replacement therapy type on pulmonary functions in postmenopausal women. Maturitas. 2003;46(3):213-8.
Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(5):472-8.
Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. The lancet oncology. 2008;9(7):649-56.
Siegfried JM, Hershberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Seminars in oncology. 2009; 36(6):524-31.
Oton AB, Belani C, Cai C, Owonikoko T, Gooding W, Siegfried J, et al. Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: An analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. In: Oncology ASoC, editor. 2006 ASCO Annual Meeting Proceedings; June 2006. Journal of Clinical Oncology: American Society of Clinical Oncology; 2006. p. 7038.
Albain KS, Unger JM, Gotay CC, Davies M, Edelman M, Herbst RS, et al. Toxicity and survival by sex in patients with advance non-small cell lung carcinoma on modern Southwest Oncology Group (SWOG) trials. In: Oncology ASoC, editor. 2007 Anual Meeting Proceedings; June 2006. J Clin Oncol: American Society of Clinical Oncology; 2007. p. 7549.
Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(1):154-64.
Zhao G, Zhao S, Wang T, Zhang S, Lu K, Yu L, et al. Estrogen receptor beta signaling regulates the progression of Chinese non-small cell lung cancer. The Journal of steroid biochemistry and molecular biology. 2011;124(1-2):47-57.
Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H. Suppression of estrogen actions in human lung cancer. Molecular and cellular endocrinology. 2011;340(2):168-74.
Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. The Journal of steroid biochemistry and molecular biology. 2009; 116(1-2):102-9.
Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, et al. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011;76(9):910-20.
Rodriguez-Lara V, Pena-Mirabal E, Baez-Saldana R, Esparza- Silva AL, Garcia-Zepeda E, Cerbon Cervantes MA, et al. Estrogen Receptor Beta and CXCR4/CXCL12 Expression: Differences by Sex and Hormonal Status in Lung Adenocarcinoma. Arch Med Res. 2014.
Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. The Journal of thoracic and cardiovascular surgery. 2009;137(3):615-21.
Baik CS, Eaton KD. Estrogen signaling in lung cancer: an opportunity for novel therapy. Cancers (Basel). 2012;4(4):969-88.
Chen YM, Perng RP, Yang KY, Lin WC, Wu HW, Liu JM, et al. A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable nonsmall- cell lung cancer. Am J Clin Oncol. 2000;23(1):13-7.
Chen Y, Perng RP, Yang KY, Lin WC, Wu HW, Tsai CM, et al. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer. 2000;29(2):139-46.
Lara PN, Jr., Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, et al. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001;48(1):22-8.
Full text